Beranda › Kanker Lambung › Michigan › Detroit
Uji klinis Kanker Lambung di Detroit, MI
16 studi untuk Kanker Lambung mencari peserta di lokasi sekitar Detroit (dalam radius sekitar 30 mil). Buka studi untuk melihat kriteria peserta dan cara menghubungi tim studi.
Teks studi resmi (Bahasa Inggris)
Merekrut peserta untuk studi di sini? Tampilkan di bagian atas halaman ini — $99 selama 30 hari →
The Vanguard Study: Testing a New Way to Screen for Cancer
Menerima pesertaSukarelawan sehat diterima
- Henry Ford Hospital, Detroit
- Henry Ford Medical Center - Detroit Northwest, Detroit
Studying the PAGODA Algorithm for Chemotherapy Dose Changes to Prevent Unplanned Treatment Delays
Menerima pesertaSukarelawan sehat diterima
- Henry Ford Health Saint John Hospital, Detroit
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Menerima pesertaStudi observasionalSukarelawan sehat diterima
- Henry Ford Hospital, Detroit
- Henry Ford Health Saint John Hospital, Detroit
Phase 3 Study of Cadonilimab Combined With Chemotherapy vs Chemotherapy in Combination With or Without Nivolumab for the 1L Treatment of Participants With HER2-negative, Previously Untreated, Unresectable or Metastatic Gastric/GEJ Adenocarcinoma
Menerima pesertaFase 3
- Henry Ford Health, Detroit
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
Menerima pesertaFase 1
- Barbara Ann Karmanos Cancer Institute, Detroit
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
Menerima pesertaFase 1
- Barbara Ann Karmanos Cancer Institute, Detroit
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
Menerima pesertaFase 1
- Karmanos Cancer Institiute, Detroit
A Phase 1/1b Study of IAM1363 in HER2 Cancers
Menerima pesertaFase 1
- Henry Ford Cancer Institute, Detroit
A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
Menerima pesertaFase 1/2
- Brigitte Harris Cancer Pavilion BHCP, Detroit
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
Menerima pesertaFase 1/2
- Karmanos Cancer Institute, Detroit
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Menerima pesertaFase 1/2
- Henry Ford Cancer Institute, Detroit
Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors
Menerima pesertaFase 1
- Investigative Site #120, Detroit
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
Menerima pesertaFase 1
- Karmanos Cancer Institute, Detroit
A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors
Menerima pesertaFase 1
- Henry Ford Health System, Detroit
Sacituzumab Govitecan in Combination With Capecitabine for Advanced Gastrointestinal Cancers After Progression on Standard Therapy
Menerima pesertaFase 1
- Henry Ford Cancer-Detroit, Detroit
A Beta-only IL-2 ImmunoTherapY Study
Menerima pesertaFase 1/2
- Karmanos Cancer Institute, Detroit
Uji klinis Kanker Lambung di kota lain
- Houston, TX42 studi
- Boston, MA32 studi
- New York City, NY31 studi
- Nashville, TN28 studi
- Baldwin Park, CA22 studi
- Los Angeles, CA22 studi
- Arlington, VA20 studi
- Dallas, TX19 studi
- San Antonio, TX19 studi
- Grand Rapids, MI18 studi
- St. Louis, MO18 studi
- Chicago, IL16 studi
Studi lain di Detroit
- Kanker Paru Non-Sel Kecil44 studi
- Kanker Payudara33 studi
- Kanker (semua jenis)29 studi
- Kanker Kolorektal26 studi
- Kanker Ovarium26 studi
- Kanker Metastatik24 studi
- Kanker Prostat22 studi
- Kanker Endometrium21 studi
- Kanker Paru20 studi
- Mieloma Multipel19 studi
- Karsinoma Sel Skuamosa Kepala dan Leher15 studi
- Leukemia Mieloid Akut14 studi
Dari ClinicalTrials.gov, data diambil 6 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.